Klotho Neurosciences, Inc. (NASDAQ: KLTO)

Klotho Neurosciences, Inc. (NASDAQ: KLTO)

Unlocking the Anti‑Aging Power of α‑Klotho — pioneering cell and gene therapies to transform the treatment of neurodegenerative disorders with disease‑modifying, potentially life‑extending biologics.

Life-Saving Innovations. Game-Changing Investments.

Why Invest in Klotho Neurosciences?

First‑in‑class α‑Klotho Gene Platform

Exclusive global license for a patented secreted splice variant of the α‑Klotho gene

(s‑KL), with IP protection across the U.S., Europe, and China.

Rapid Clinical Advancement

KLTO‑202, our lead AAV‑based α‑Klotho gene therapy for ALS, is advancing to clinical stage—manufacturing underway and IND filing expected within 8–12 months.

Clear Path in Major Markets Targeting high‑unmet-need conditions: ALS, Alzheimer’s,

Parkinson’s and broader age-related cognitive decline. Aging is the number‑one risk

factor for these disorders; we aim to address root causes, not symptoms.

Strong Financial Position & Compliance Restored

Raised >$11M via warrant exercises, extinguished all debt, now surpassing NASDAQ

shareholder‑equity thresholds. Debt‑free balance sheet ensures runway and compliance.

Experienced Leadership & Scientific Advisory Board

Founded by seasoned biotech executives, with strategic partnerships anchored at UAB/

ICREA and backed by experts in gene therapy commercialization.

Near‑Term Catalysts on the Horizon

IND submission and launch of Phase I/II ALS program (Q3 2026).

 (NASDAQ: KLTO)

Innovative Platform: α‑Klotho Gene Therapy

1.      Breakthrough Biology α‑Klotho is a master “anti‑aging” regulator shown to reverse neurodegeneration, improve cognition, reduce inflammation and oxidative stress, and clear amyloid plaques in preclinical models.

2.      Multi-Delivery Technology Our s‑KL gene construct—compatible with viral vectors, lipid complexes, recombinant protein, or ex vivo cell therapy—enables versatile deployment to maximize therapeutic reach.

3.      Therapeutic Breadth Platform designed to address a spectrum of age‑related diseases: ALS, Alzheimer’s, Parkinson’s, sarcopenia, osteoporosis, cardiovascular and renal conditions.

Investment Highlights - (NASDAQ: KLTO)

Invest in the Future, Today

Strength	Details
Proprietary IP	Exclusive worldwide rights to s‑KL gene therapy platform
Clinical Progress	KLTO‑202 entering GMP manufacturing and IND timeline
Financial Stability	$11M capital raise, debt cleared, NASDAQ-compliant equity
Experienced Team	Proven track record in biotech R&D and commercialization
Scalable Platform	Modular gene therapy tech for multiple indications
Approaching Catalysts	IND submission, investor events, early-stage bio data

We Don’t Just Disrupt — We Deliver

(NASDAQ: KLTO)

Recent Milestones

$11M funds raised & debt retirement — Debt-free, equity threshold exceeded.

Advancing ALS candidate — KLTO‑202 manufacturing live; IND expected in 8–12 months

Investor visibility — Featured at Biotech Showcase 2025 during JPM Week.

Vision & Strategy

Klotho Neurosciences is on a mission to reshape the future of brain health. By harnessing our patented α‑Klotho gene therapy, we aim to deliver life-changing, disease-altering treatments across neurodegenerative conditions. Our approach integrates:

Robust clinical pipeline with ALS lead candidate

Expansion potential (Alzheimer’s, Parkinson’s, diagnostics)

Partner and licensing opportunities to accelerate development

Scalable infrastructure supporting commercialization goals

Join Us in Defining the Next Era of Neurotherapeutics

Klotho offers:

A compelling science‑backed platform with broad therapeutic reach

Upcoming milestones set to significantly increase value

Solid financial footing with minimal dilution risk

Experienced leadership and scalable operational focus

We invite forward-looking investors to engage with our vision, support our clinical journey, and shape the future of disease-modifying neurotherapeutics.

(NASDAQ: KLTO)

Contact Investor Relations Email: IR@klothoneuro.com | Jeff LeBlanc, CFO

DISCLAIMER

This landing page is intended for informational purposes only and does not constitute investment advice. Forward-looking statements are made under the safe harbor provisions of relevant securities legislation.

Snapmediagroup.net and Vanderbiltreport.com are owned and operated by SMG a US-based corporation. We have received compensation of up to $100,000 for the profiling of Klotho Neurosciences, Inc. (Nasdaq: KLTO) starting on July , 2025.

It is important to note that we do not own any shares in KLTO : NASDAQ.